A Study for Tysabri Participant Preference

Condition:   Relapsing-Remitting Multiple Sclerosis (RRMS) Intervention:   Drug: Natalizumab Sponsor:   Biogen Recruiting

Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials